Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
Marker Therapeutics was awarded a $2.6 million FDA Orphan Products Clinical Trials grant to fund a Phase 1 study of its lead MAR-T cell therapy MT-601 in locally advanced unresectable pancreatic cancer, with clinical initiation targeted for Q1 2027. The grant is highly competitive — the FDA selected only six projects from 66 applications in fiscal 2026 — and provides non-dilutive funding plus external validation of the MAR-T platform.
Key figures
- Drug Name
- MT-601
- Deal Value Usd
- 2600000
- Phase Of Trial
- Phase 1
- Study initiation
- Q1 2027
- Disease control rate
- 84.6%
- Fda applications fy2026
- 66
- Median overall survival
- 14.1 months
- Fda projects funded fy2026
- 6
- Median duration of response
- 7.5 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.